Trends & Forecasts

Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track

Why the ability to design therapeutics based on glycobiology will make a mark on pharma R&D.

Thoughts on the US National Institutes of Health and its role in funding research for non-opioid therapeutics.

Neal Baer, editor of a collection of essays on CRISPR, says we must not overlook the dark side of the technology.

Experts explain why these are two important areas to watch in the near future of pharma R&D.

We take a deep dive into key industry trends off the back of Clarivate’s Drugs to Watch 2025 report

In part 2 of our roundtable discussion, thought leaders discuss what Trump could do for drug pricing and whether change is to be feared or embraced.

We speak with Clarivate about their report listing eleven key drugs to watch in 2025.

And getting the right people involved from the start. Here’s why collaboration is key for successful clinical development.

Biden pushed drug pricing reforms, whereas Trump is known for deregulation. What does this mean for pharma?